Ticagrelor
Ticagrelor, produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).
| Catalog Number | T0179 |
| Alternative Name(s) | AR-C 126532XX , AZD6140 |
| Research Area | Metabolism|||Neuroscience|||GPCR/G Protein |
| Molecular Formula | C23H28F2N6O4S |
| CAS# | 274693-27-5 |
| Purity | 100.00% |
| SMILES | CCCSc1nc2c(nnn2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)c(N[C@@H]2C[C@H]2c2cc(F)c(F)cc2)n1 |
| Size | 200 mg |
| Supplier Page | https://www.targetmol.com/compound/Ticagrelor |
| Additional Information | https://www.targetmol.com/datasheet/T0179 |